NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


[profilepress-login id="1"]

Don't have an account? Subscribe

ADVERTISEMENT

ADVERTISEMENT

New dawn for clinical research at Wexford

By Dermot - 03rd May 2019

At the Ireland East Hospital Group & University College Dublin Clinical Academic Reserch Directorate Launch in Wexford General Hospital on Monday morning were Professor Andrew Deeks, President University College Dublin, Lily Byrnes, General Manager Wexford General Hospital. Mary Day, CEO Ireland East Hospital Group, Professor Peter Doran , UCD Clinical Research Centre & IEHG Clinical Academic Research Directorate.
Pictured at the launch of the University College Dublin (UCD) clinical research centre at Wexford General Hospital are (L-R): Prof Andrew Deeks, President, UCD; Ms Lily Byrnes, General Manager, Wexford General Hospital; Ms Mary Day, CEO, Ireland East Hospital Group (IEHG); and Prof Peter Doran, Director of Clinical Research, UCD.The new centre will link to research facilities and supports provided by the UCD School of Medicine and to wider studies carried out in the IEHG. UCD opened clinical research centres at the Mater
Misericordiae University Hospital, Dublin and St Vincent’s University Hospital, Dublin in 2006. Since then, it has undertaken over 200 studies and 130 clinical trials with patients who have various conditions, including end-stage kidney disease, pulmonary fibrosis and cancer.

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT